Clinical trials: New Onset Diabetes After Transplant
New Onset Diabetes Mellitus After Renal Transplantation
Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation
New onset diabetes after transplantation (NODAT) is a frequent and feared complication after kidney transplantation and leads to an increase in cardiovascular complications as well as in the rate of graft loss.
- Trial name
- ISINODAT (NCT01268995)
- Testing
- Cyclosporine A, Tacrolimus
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
New Onset Diabetes After Transplant, Diabetes Mellitus
"Outcome of Diabetes Education Among Renal Transplant Recipients With New Onset Diabetes After Transplantation (NODAT)"
Introduction: Diabetes is a chronic disease that requires lifelong self care behavior. Successful treatment of chronic diseases is closely associated with the education of both patients and their relatives.
- Trial name
- NODAT-ES (NCT04030013)
- Testing
- group education
- Where
- Kuwait
- Volunteers
- 210 people
- Sponsor
- Dasman Diabetes Institute
Prevention of New Onset Diabetes Among Kidney Transplant Patients
A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Specific Aim 1: To determine the clinical efficacy of early initiation of insulin therapy in decreasing the incidence of NODAT among de novo kidney transplant patients with manifested post-transplant hyperglycemia during the…
- Trial name
- ITP-NODAT (NCT01683331)
- Testing
- Insulin treatment for hyperglycemia
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- University of Michigan
Hyperglycemia
Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients
This study aims to assess the effects of early basal insulin therapy in previously non-diabetic de novo kidney transplant patients in reducing the incidence of new onset diabetes in particular and abnormal glucose metabolism in…
- Trial name
- ITP-NODAT (NCT03507829)
- Testing
- Human insulin isophane, Humulin N (Eli Lilly), Standard of care, Insulin lispro, Humalog (Eli Lilly) in insulin pump
- Volunteers
- 263 people
- Sponsor
- Medical University of Vienna
Disorder Related to Renal Transplantation, Diabetes
Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period
Post-transplant diabetes affects 15 to 20% of renal transplant patients and contributes to increased morbidity and reduced survival of transplants and patients.
- Trial name
- PRODIG (NCT02849899)
- Testing
- Vildagliptin
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Transplantation
Prediction of NODAT After Renal Transplantation
A statistical analysis of the predictive value of OGTT and FPG testing executed as part of standard clinical practice after renal transplantation for the diagosis of new-onset diabetes mellitus after transplantation.
- Trial name
- NCT00442988
- Where
- Belgium
- Volunteers
- 360 people
- Sponsor
- KU Leuven
New Onset Diabetes After Transplant, Kidney Transplant; Complications
Efficacy and Safety of Empagliflozin in NODAT
This is an open label, randomized controlled study. We'd like to access the safety and effects of empagliflozin compared with linagliptin in new-onset diabetes after kidney transplantation patients.
- Trial name
- NCT03642184
- Testing
- Empagliflozin, Linagliptin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- RenJi Hospital
New Onset Diabetes After Transplantation
Continuous Glucose Monitoring in Peri-operative Period in Kidney Transplant Recipients
his study aims to utilize Continuous Glucose Monitoring (CGM) to observe glucose fluctuations in kidney transplant recipients and predict New-Onset Diabetes After Transplantation (NODAT) based on these patterns.
- Trial name
- NCT06012799
- Testing
- continuous glucose monitoring
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
New Onset Diabetes After Transplantation
Post-Transplant Diabetes Outcomes Prediction
Chronic Kidney disease (CKD) is a major global health burden and represents one of the most common non-communicable diseases. In Europe, CKD affects over 50 million people, representing approximately 10% of the adult population.
- Trial name
- PERCEIVE (NCT07512804)
- Testing
- Whole genome sequencing (WGS)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Diabetes Mellitus
Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation
Balancing immunosuppressive treatment in organ transplantation in order to achieve effective prevention of rejection on one side and avoidance of negative side effects on the other side is a major challenge, leading to developing…
- Trial name
- SAILOR (NCT02083991)
- Testing
- Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon
- Where
- Sweden
- Volunteers
- 224 people
- Sponsor
- Vastra Gotaland Region
Kidney; Complications, Allograft
Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients
To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation in the…
- Trial name
- PROTECT (NCT02036554)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Seoul St. Mary's Hospital
Cirrhosis, Liver, Diabetes Mellitus Risk
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation.
- Conditions
- Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder
- Trial name
- NCT06950788
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Type 2 Diabetes, End Stage Renal Disease
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
- Trial name
- NCT00936663
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Nebraska
New Onset Diabetes After Transplant, Kidney Transplantation
Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
This study is being conducted to determine if belatacept is an appropriate alternative immunosuppressive medication (reducing the immune system's effect) when a kidney transplant patient develops new onset diabetes after…
- Trial name
- NCT01875224
- Testing
- Belatacept, Tacrolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Arizona
Posttransplant Diabetes Mellitus
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
The purpose of this study is to determine whether sitagliptin is effective in preventing the development of new-onset diabetes after kidney transplant (NODAT).
- Trial name
- NCT01928199
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Diabetes
Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept
With improvements in patient and graft survival, increasing attention has been placed on complications that contribute to long-term patient morbidity and mortality.
- Trial name
- NODAT (NCT02095418)
- Testing
- Mycophenolate mofetil, Corticosteroids, Corticosteroids, Mycophenolate mofetil
- Where
- 5 sites in South Korea
- Volunteers
- 152 people
- Sponsor
- Samsung Medical Center
Diabetes Mellitus, Adult-Onset
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression.
- Trial name
- 01-DMPT (NCT01002339)
- Testing
- Tacrolimus with rapid steroid withdrawal, Tacrolimus with steroids minimization, CsA with steroid minimization
- Where
- 10 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Armando Torres Ramírez
Diabetes Mellitus
Vildagliptin in New Onset Diabetes After Transplantation
The purpose of this study is to determine whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed New Onset Diabetes after Transplantation (NODAT).
- Trial name
- VINODAT (NCT00980356)
- Testing
- Vildagliptin
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna